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Kidney transplantation in Hong Kong: where are we and where
to go?
E d i t o r i a l
Entering the era of the new millennium, there are still a
number of issues to be tackled in the long-term care of
our renal failure patients. Most nephrologists would agree
that kidney transplantation is probably the best treatment
for our uremic patients. The benefits of renal transplan-
tation have usually been described in terms of a better
quality of life and reduced medical expenses while very
few studies have proved the prolongation of life in kid-
ney transplant. Recently, Wolfe et al (1) studied 46164
dialysis patients on a waiting list for transplantation, and
23275 of who received a first cadaveric transplant be-
tween 1991 and 1997 in USA. They found that patients
who are well enough to be placed on a waiting list for
transplantation have about a 68 % reduction in the long-
term risk of death once they have received a renal
transplant, as compared with those who remain on the
waiting list and did not have a chance for the kidney
transplant (1).
Knowing this benefit of transplantation on long-term
survival, we, nephrologists, have obvious limitations. In
Hong Kong, there are currently about 1000 dialysis pa-
tients waiting for a kidney but unfortunately the cadav-
eric kidney donation in 1999 was only 47. With the scarce
supply of kidneys, the allocation of these precious or-
gans is obviously of concern to all parties: doctors, nurses
and patients. Also, how do our patients do after the kid-
ney transplant? What are the survival rates and what are
the complication rates? In this issue, we have two pa-
pers discussing on two important aspects of renal trans-
plantation in Hong Kong: one on the issue of point scor-
ing of kidney allocation (2) and the other on the rate of
post-kidney-transplant malignancies (3).
Hawkins (2) described the revised allocation system for
cadaveric kidney, which was introduced in 1996 after
endorsement from the Central Renal Committee of Hos-
pital Authority of Hong Kong. The determining factors
for allocation are age of patients, years on waiting list
and HLA score. Bonus points were given to pediatric
patients while donor kidneys will be given to zero-mis-
matched recipients across the regions. It was concluded
in the paper that the 3-year actuarial graft survival rate
under this system was 83%, which was very respectable.
Recently, Hariharan et al (4) reported the 1-year graft
survival in cadaveric transplantation in United States was
87.7% in 1996 that already showed a marked improve-
ment compared with 75.7% in 1988. It is quite certain
that the allocation system could address more to the vari-
ous needs of our patients and at the same time having
very good graft results.
Such promising graft results would not be possible with-
out  the advances in  the immunosuppressive
armaments that evolved over the years. The era of
immunosuppressants was initially based on the admin-
istration of glucocorticoids and azathioprine. In the early
Eighties, the introduction of monoclonal antibodies di-
rected against the CD3 molecule and of cyclosporine
further reduced the incidence of acute rejection episodes.
The discovery of new immunosuppressive agents, such
as tacrolimus, rapamycin, interleukin-2 monoclonal
antibodies, and mycophenolate mofetil were even more
potent and selective in targeting different immune
responses. There is always a price to pay and the two
major problems are infections and malignancies in our
transplant recipients.
Chau et al (3) compiled data from all Hong Kong trans-
plant centers and described the largest Hong Kong se-
ries of post-transplant-malignancies in 1687 renal trans-
plant patients with 1714 grafts from 1972 to 2000. There
were 42 malignancies with an overall incidence of
2.4%. This compared very similar to a recent report from
Danpanich and Kasiske (5) who reviewed 1500 patients
with kidney transplantation at Hennepin County Medi-
cal Center between 1963, and 1997. They found 87
tumors in 88 patients. The three most common post-kid-
ney-transplant malignancies in Hong Kong are post-
transplant lymphoproliferative disorder (PTLD), hepa-
tocellular carcinoma and Kaposi's sarcoma, all with vi-
ruses as important causative agents. Yang et al (6), in a
recent Taiwan report, showed that the most common
types of post-renal-transplant cancer were transitional
cell carcinoma (TCC) of the urinary tract (8/25), and
hepatoma (8/25), followed by two cases of Kaposi's sar-
coma in 390 renal transplant recipients who underwent
renal transplantation between 1983 and 1996. Their over-
all incidence of post-transplant malignancies was 6.2%.
Interestingly, the Taiwan series did not show such a high
incidence of PTLD as in Hong Kong. The transplant
community in Hong Kong has been seeing an increas-
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ing number of post-transplant malignancies and indeed
that may be related to immunosuppressants administered,
either in very high dosage or in the combination of very
potent drugs and antibodies. Chau et al (3) did find pa-
tients who developed tumors especially those who died
from malignancies had a higher incidence of severe re-
jections requiring ATG or OKT3 antibodies. Prevention
is always better than cure. Transplant clinicians need to
be very cautious in administering high dose
immunosuppressants or using combination of very po-
tent drugs as prophylaxis or treatment. Malignancy sur-
veillance is important and that is particularly true in our
hepatitis B carriers or those who smoke. Clinicians need
to be constant on the alert that viral infections in patients,
like Hepatitis B virus(HBV), Epstein-Barr virus (EBV)
and Human Herpes virus 8 (HHV 8), as pathogenetic
milieu. A high level of suspicion is required. Novel ways
of treatment strategies for transplant malignancies need
to be developed (7). Though marked reduction or cessa-
tion of immunosuppressants will sometimes improve the
malignancy, it will also end up with graft loss. Every
one of us wants to preserve the precious graft as far as
possible without jeopardizing the patient's survival.
Indeed, Hawkins (2) reported that 9.5% (N = 16) of his
series of patients died within 34 months of transplant
and half occurred within 4 months after transplant. In
only one of these cases was rejection listed a contribu-
tory cause of death. There is a high chance that malig-
nancy and infection be the two major leading causes for
such mortality. And once again, the balance of preven-
tion of rejection and the "over" immunosuppression
needs to be addressed.
What are the future directions? Worldwide, scientists are
actively trying to achieve tolerance to an organ graft,
the "Holy Grail" of transplant. New immunosuppressive
agents, both drugs and biological agents, are being
evaluated. The interest in xenotransplantation is revived
due to insufficient human organs or tissues. Molecular
biology and genetic engineering may make cloning of
tissues or even organs possible, in future. In Hong Kong,
the scarce supply of kidneys calls for some novel ways
of improving organ procurement rate. That takes a lot of
education, understanding and dedication from various
parties: nephrologists, neurosurgeons, intensivists,
nurses, transplant coordinators and the general public at
large. So far, we have a very successful long-term out-
come of the graft. Transplant physicians need to look
even more closely to prevent the short- and long-term
patient complications other than rejection like
malignancy, infections and cardiovascular disease. Pa-
tients die with a functioning graft is the last thing any-
one would like to see. Actually, stringent and cautious
reduction of immunosuppressive drugs should be exer-
cised to prevent the long-term complications of
malignancy, infections and even cardiovascular disease,
and have an extra bonus of decrease in drug cost. The
judicious use of the existing and the new and potent
immunosuppressants, which are coming up one after
another, is crucial.
Philip Kam-Tao Li
Editor-in-Chief
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